Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 extension study for chronic rhinosinusitis with nasal polyps
CTR20241448Phase 2Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- May 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bosakitug in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Nanjing Shunxin Pharmaceutical. Started May 2024; status: completed.
02
Drugs
bosakitug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20241448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241448.